---
input_text: 'Mutations in GDAP1: autosomal recessive CMT with demyelination and axonopathy.BACKGROUND:
  Mutations in the ganglioside-induced differentiation-associated protein 1 gene (GDAP1)
  were recently shown to be responsible for autosomal recessive (AR) demyelinating
  Charcot-Marie-Tooth disease (CMT) type 4A (CMT4A) as well as AR axonal CMT with
  vocal cord paralysis. METHODS: The coding region of GDAP1 was screened for the presence
  of mutations in seven families with AR CMT in which the patients were homozygous
  for markers of the CMT4A locus at chromosome 8q21.1. RESULTS: A nonsense mutation
  was detected in exon 5 (c.581C>G, S194X), a 1-bp deletion in exon 6 (c.786delG,
  G262fsX284), and a missense mutation in exon 6 (c.844C>T, R282C). CONCLUSIONS: Mutations
  in GDAP1 are a frequent cause of AR CMT. They result in an early-onset, severe clinical
  phenotype. The range of nerve conduction velocities (NCV) is variable. Some patients
  have normal or near normal NCV, suggesting an axonal neuropathy, whereas others
  have severely slowed NCV compatible with demyelination. The peripheral nerve biopsy
  findings are equally variable and show features of demyelination and axonal degeneration.'
raw_completion_output: |-
  primary_disease: Charcot-Marie-Tooth disease (CMT)

  medical_actions: screening for GDAP1 mutations; nerve conduction velocity (NCV) tests; peripheral nerve biopsy

  symptoms: demyelination; axonopathy; vocal cord paralysis

  chemicals: 

  action_annotation_relationships: screening for GDAP1 mutations TREATS demyelination IN Charcot-Marie-Tooth disease (CMT); screening for GDAP1 mutations TREATS axonopathy IN Charcot-Marie-Tooth disease (CMT); nerve conduction velocity (NCV) tests TREATS demyelination IN Charcot-Marie-Tooth disease (CMT); nerve conduction velocity (NCV) tests TREATS axonopathy IN Charcot-Marie-Tooth disease (CMT); peripheral nerve biopsy TREATS demyelination IN Charcot-Marie-Tooth disease (CMT); peripheral nerve biopsy TREATS axonopathy IN Charcot-Marie-Tooth disease (CMT)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  peripheral nerve biopsy TREATS axonopathy IN Charcot-Marie-Tooth disease (CMT)

  ===

extracted_object:
  primary_disease: MONDO:0015626
  medical_actions:
    - screening for GDAP1 mutations
    - nerve conduction velocity (NCV) tests
    - MAXO:0035087
  symptoms:
    - HP:0011096
    - axonopathy
    - HP:0001605
  action_annotation_relationships:
    - subject: screening for GDAP1 mutations
      predicate: TREATS
      object: HP:0011096
      qualifier: MONDO:0015626
      subject_extension: GDAP1 mutations
    - subject: screening
      predicate: TREATS
      object: axonopathy
      qualifier: MONDO:0015626
      subject_extension: GDAP1 mutations
    - subject: nerve conduction velocity tests
      predicate: TREATS
      object: HP:0011096
      qualifier: MONDO:0015626
    - subject: nerve conduction velocity (NCV) tests
      predicate: TREATS
      object: axonopathy
      qualifier: MONDO:0015626
    - subject: MAXO:0035087
      predicate: TREATS
      object: HP:0011096
      qualifier: MONDO:0015626
    - subject: MAXO:0035087
      predicate: TREATS
      object: axonopathy
      qualifier: MONDO:0015626
named_entities:
  - id: MONDO:0008891
    label: Brown-Vialetto-Van Laere syndrome
  - id: MAXO:0009004
    label: exome sequencing
  - id: HP:0000407
    label: sensorineural hearing loss
  - id: HP:0002093
    label: respiratory insufficiency
  - id: HP:0010871
    label: sensory ataxia
  - id: HP:0000648
    label: optic atrophy
  - id: CHEBI:17015
    label: riboflavin
  - id: HP:0012469
    label: infantile spasms
  - id: HP:0000789
    label: infertility
  - id: HP:0005268
    label: miscarriage
  - id: CHEBI:16709
    label: pyridoxine
  - id: CHEBI:18405
    label: pyridoxal 5'-phosphate
  - id: CHEBI:27306
    label: vitamin B6
  - id: CHEBI:24041
    label: flavin mononucleotide
  - id: HP:0001250
    label: seizures
  - id: MONDO:0009974
    label: Familial hemophagocytic lymphohistiocytosis
  - id: MAXO:0010030
    label: bone marrow transplantation (BMT)
  - id: CHEBI:28901
    label: busulfan
  - id: CHEBI:4027
    label: cyclophosphamide
  - id: CHEBI:4911
    label: etoposide
  - id: MAXO:0000757
    label: infusion
  - id: CHEBI:41264
    label: busulfan (BU), cyclophosphamide (CP), etoposide (VP16), antithymocyte globulin
      (ATG)
  - id: MAXO:0000750
    label: conditioning regimen
  - id: CHEBI:73896
    label: gene therapy (GT)
  - id: MONDO:0009666
    label: Holocarboxylase synthetase deficiency
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: HP:0001942
    label: Metabolic acidosis
  - id: CHEBI:15956
    label: Biotin
  - id: HP:0003256
    label: Coagulopathy
  - id: CHEBI:48669
    label: Tranexamic acid
  - id: CHEBI:48675
    label: antifibrinolytic agents
  - id: MONDO:0020300
    label: Autosomal dominant nocturnal frontal lobe epilepsy
  - id: CHEBI:3387
    label: Carbamazepine
  - id: MONDO:0000903
    label: Myoclonus-dystonia
  - id: MAXO:0000943
    label: Deep Brain Stimulation
  - id: HP:0001252
    label: Hypotonia
  - id: MONDO:0005338
    label: Primary open-angle glaucoma (POAG)
  - id: MAXO:0001082
    label: Trabeculectomy
  - id: MAXO:0000960
    label: Viscocanalostomy
  - id: HP:0007906
    label: Elevated intraocular pressure (IOP)
  - id: HP:0000253
    label: Progressive microcephaly
  - id: HP:0001263
    label: Global developmental delay
  - id: HP:0000365
    label: Hearing loss
  - id: HP:0100785
    label: Insomnia
  - id: CHEBI:15681
    label: GM3
  - id: CHEBI:28892
    label: Ganglioside
  - id: MAXO:0001298
    label: therapies
  - id: MAXO:0000950
    label: Supportive care
  - id: CHEBI:8378
    label: Prednisolone
  - id: MONDO:0015626
    label: Charcot-Marie-Tooth disease (CMT)
  - id: MAXO:0035087
    label: peripheral nerve biopsy
  - id: HP:0011096
    label: demyelination
  - id: HP:0001605
    label: vocal cord paralysis
